AT2 receptor agonist C21
(Synonyms: AT2 receptor agonist C21) 目录号 : GC39554
An AT2 receptor agonist
Cas No.:477775-14-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
AT2 agonist C21 is an agonist of the angiotensin II type 2 (AT2) receptor.1 It selectively binds to the AT2 receptor over the AT1 receptor (Kis = 0.4 and >10 ?M, respectively). AT2 agonist C21 (0.1 ?M) induces neurite outgrowth in NG 108-15 cells. It reduces mean arterial blood pressure in anaesthetized spontaneously hypertensive rats (SHRs) when administered at a dose of 0.05 mg/kg. AT2 agonist C21 (0.03 mg/kg) reduces right ventricle hypertrophy and fibrosis, as well as lung interstitial and perivascular fibrosis, in a rat model of pulmonary hypertension induced by monocrotaline .2 It increases survival and reduces neurological deficits in a mouse model of cerebral ischemia induced by middle cerebral artery occlusion (MCAO) when administered at the same dose.3
1.Wan, Y., Wallinder, C., Plouffe, B., et al.Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonistJ. Med. Chem.47(24)5995-6008(2004) 2.Bruce, E., Shenoy, V., Rathinasabapathy, A., et al.Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosisBr. J. Pharmacol.172(9)2219-2231(2004) 3.Schwengel, K., Namsolleck, P., Lucht, K., et al.Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in miceJ. Mol. Med. (Berl.)94(8)957-966(2016)
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1025 mL | 10.5126 mL | 21.0252 mL |
| 5 mM | 0.4205 mL | 2.1025 mL | 4.205 mL |
| 10 mM | 0.2103 mL | 1.0513 mL | 2.1025 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。